O	0	5	Phase
O	6	9	III
O	10	20	comparison
O	21	23	of
B-intervention	24	33	tamoxifen
O	34	40	versus
B-control	41	50	tamoxifen
I-control	51	55	plus
I-control	56	63	ovarian
I-control	64	72	function
I-control	73	84	suppression
O	85	87	in
O	88	101	premenopausal
O	102	107	women
O	108	112	with
O	113	117	node
O	117	118	-
O	118	126	negative
O	126	127	,
O	128	135	hormone
O	136	144	receptor
O	144	145	-
O	145	153	positive
O	154	160	breast
O	161	167	cancer
O	168	169	(
O	169	170	E
O	170	171	-
O	171	175	3193
O	175	176	,
O	177	180	INT
O	180	181	-
O	181	185	0142
O	185	186	)
O	186	187	:
O	188	189	a
O	190	195	trial
O	196	198	of
O	199	202	the
O	203	210	Eastern
O	211	222	Cooperative
O	223	231	Oncology
O	232	237	Group
O	237	238	.

O	239	242	The
O	243	250	effects
O	251	253	of
O	254	261	ovarian
O	262	270	function
O	271	282	suppression
O	283	284	(
O	284	287	OFS
O	287	288	)
O	289	291	on
O	292	300	survival
O	301	304	and
O	305	312	patient
O	312	313	-
O	313	321	reported
O	322	330	outcomes
O	331	335	were
O	336	345	evaluated
O	346	348	in
O	349	350	a
O	351	356	phase
O	357	360	III
O	361	366	trial
O	367	369	in
O	370	375	which
O	376	389	premenopausal
O	390	395	women
O	396	400	were
O	401	409	randomly
O	410	418	assigned
O	419	421	to
O	422	431	tamoxifen
O	432	436	with
O	437	439	or
O	440	447	without
O	448	451	OFS
O	451	452	.

B-eligibility	453	466	Premenopausal
I-eligibility	467	472	women
I-eligibility	473	477	with
I-eligibility	478	486	axillary
I-eligibility	487	491	node
I-eligibility	491	492	-
I-eligibility	492	500	negative
I-eligibility	500	501	,
I-eligibility	502	509	hormone
I-eligibility	510	518	receptor
I-eligibility	518	519	-
I-eligibility	519	527	positive
I-eligibility	528	534	breast
I-eligibility	535	541	cancer
I-eligibility	542	548	tumors
I-eligibility	549	558	measuring
I-eligibility	559	560	â‰¤
I-eligibility	561	562	3
I-eligibility	563	565	cm
O	566	570	were
O	571	579	randomly
O	580	588	assigned
O	589	591	to
O	592	601	tamoxifen
O	602	607	alone
O	608	614	versus
O	615	624	tamoxifen
O	625	629	plus
O	630	633	OFS
O	633	634	;
O	635	643	adjuvant
O	644	656	chemotherapy
O	657	660	was
O	661	664	not
O	665	674	permitted
O	674	675	.

O	676	683	Primary
O	684	687	end
O	688	694	points
O	695	699	were
B-outcome-Measure	700	707	disease
I-outcome-Measure	707	708	-
I-outcome-Measure	708	712	free
I-outcome-Measure	713	721	survival
I-outcome-Measure	722	723	(
I-outcome-Measure	723	726	DFS
I-outcome-Measure	726	727	)
O	728	731	and
B-outcome-Measure	732	739	overall
I-outcome-Measure	740	748	survival
I-outcome-Measure	749	750	(
I-outcome-Measure	750	752	OS
I-outcome-Measure	752	753	)
O	753	754	.

O	755	764	Secondary
O	765	768	end
O	769	775	points
O	776	784	included
B-outcome-Measure	785	793	toxicity
I-outcome-Measure	794	797	and
I-outcome-Measure	798	805	patient
I-outcome-Measure	805	806	-
I-outcome-Measure	806	814	reported
I-outcome-Measure	815	823	outcomes
O	823	824	.

O	825	832	Patient
O	832	833	-
O	833	841	reported
O	842	849	outcome
O	850	854	data
O	855	863	included
O	864	870	health
O	870	871	-
O	871	878	related
O	879	886	quality
O	887	889	of
O	890	894	life
O	894	895	,
O	896	906	menopausal
O	907	915	symptoms
O	915	916	,
O	917	920	and
O	921	927	sexual
O	928	936	function
O	936	937	.

O	938	943	These
O	944	948	were
O	949	958	evaluated
O	959	961	at
O	962	970	baseline
O	970	971	,
O	972	973	6
O	974	980	months
O	980	981	,
O	982	984	12
O	985	991	months
O	991	992	,
O	993	996	and
O	997	1001	then
O	1002	1010	annually
O	1011	1014	for
O	1015	1017	up
O	1018	1020	to
O	1021	1022	5
O	1023	1028	years
O	1029	1034	after
O	1035	1047	registration
O	1047	1048	.

O	1049	1051	In
O	1052	1055	all
O	1055	1056	,
B-total-participants	1057	1060	345
O	1061	1074	premenopausal
O	1075	1080	women
O	1081	1085	were
O	1086	1094	enrolled
O	1094	1095	:
B-intervention-participants	1096	1099	171
O	1100	1102	on
O	1103	1112	tamoxifen
O	1113	1118	alone
O	1119	1122	and
B-control-participants	1123	1126	174
O	1127	1129	on
O	1130	1139	tamoxifen
O	1140	1144	plus
O	1145	1148	OFS
O	1148	1149	.

O	1150	1154	With
O	1155	1156	a
O	1157	1163	median
O	1164	1170	follow
O	1170	1171	-
O	1171	1173	up
O	1174	1176	of
O	1177	1178	9
O	1178	1179	.
O	1179	1180	9
O	1181	1186	years
O	1186	1187	,
O	1188	1193	there
O	1194	1197	was
O	1198	1200	no
O	1201	1212	significant
O	1213	1223	difference
O	1224	1231	between
O	1232	1236	arms
O	1237	1240	for
B-outcome	1241	1244	DFS
O	1245	1246	(
O	1246	1247	5
O	1247	1248	-
O	1248	1252	year
O	1253	1257	rate
O	1257	1258	:
B-iv-bin-percent	1259	1261	87
I-iv-bin-percent	1261	1262	.
I-iv-bin-percent	1262	1263	9
I-iv-bin-percent	1263	1264	%
O	1265	1266	v
B-cv-bin-percent	1267	1269	89
I-cv-bin-percent	1269	1270	.
I-cv-bin-percent	1270	1271	7
I-cv-bin-percent	1271	1272	%
O	1272	1273	;
O	1274	1277	log
O	1277	1278	-
O	1278	1282	rank
O	1283	1284	P
O	1285	1286	=
O	1287	1288	.
O	1288	1290	62
O	1290	1291	)
O	1292	1294	or
B-outcome	1295	1297	OS
O	1298	1299	(
O	1299	1300	5
O	1300	1301	-
O	1301	1305	year
O	1306	1310	rate
O	1310	1311	:
B-iv-bin-percent	1312	1314	95
I-iv-bin-percent	1314	1315	.
I-iv-bin-percent	1315	1316	2
I-iv-bin-percent	1316	1317	%
O	1318	1319	v
B-cv-bin-percent	1320	1322	97
I-cv-bin-percent	1322	1323	.
I-cv-bin-percent	1323	1324	6
I-cv-bin-percent	1324	1325	%
O	1325	1326	;
O	1327	1330	log
O	1330	1331	-
O	1331	1335	rank
O	1336	1337	P
O	1338	1339	=
O	1340	1341	.
O	1341	1343	67
O	1343	1344	)
O	1344	1345	.

B-outcome	1346	1351	Grade
I-outcome	1352	1353	3
I-outcome	1354	1356	or
I-outcome	1357	1363	higher
I-outcome	1364	1372	toxicity
O	1373	1376	was
O	1377	1381	more
O	1382	1388	common
O	1389	1391	in
O	1392	1395	the
O	1396	1405	tamoxifen
O	1406	1410	plus
O	1411	1414	OFS
O	1415	1418	arm
O	1419	1420	(
B-cv-bin-percent	1420	1422	22
I-cv-bin-percent	1422	1423	.
I-cv-bin-percent	1423	1424	4
I-cv-bin-percent	1424	1425	%
O	1426	1427	v
B-iv-bin-percent	1428	1430	12
I-iv-bin-percent	1430	1431	.
I-iv-bin-percent	1431	1432	3
I-iv-bin-percent	1432	1433	%
O	1433	1434	;
O	1435	1436	P
O	1437	1438	=
O	1439	1440	.
O	1440	1443	004
O	1443	1444	)
O	1444	1445	.

O	1446	1454	Patients
O	1455	1462	treated
O	1463	1467	with
O	1468	1477	tamoxifen
O	1478	1482	plus
O	1483	1486	OFS
O	1487	1490	had
O	1491	1495	more
B-outcome	1496	1506	menopausal
I-outcome	1507	1515	symptoms
O	1515	1516	,
O	1517	1522	lower
B-outcome	1523	1529	sexual
I-outcome	1530	1538	activity
O	1538	1539	,
O	1540	1543	and
O	1544	1552	inferior
B-outcome	1553	1559	health
I-outcome	1559	1560	-
I-outcome	1560	1567	related
I-outcome	1568	1575	quality
I-outcome	1576	1578	of
I-outcome	1579	1583	life
I-outcome	1584	1586	at
I-outcome	1587	1588	3
I-outcome	1588	1589	-
I-outcome	1589	1593	year
O	1594	1600	follow
O	1600	1601	-
O	1601	1603	up
O	1604	1605	(
O	1605	1606	P
O	1607	1608	<
O	1609	1610	.
O	1610	1612	01
O	1613	1616	for
O	1617	1620	all
O	1620	1621	)
O	1621	1622	.

O	1623	1634	Differences
O	1635	1645	diminished
O	1646	1650	with
O	1651	1658	further
O	1659	1665	follow
O	1665	1666	-
O	1666	1668	up
O	1668	1669	.

O	1670	1674	When
O	1675	1680	added
O	1681	1683	to
O	1684	1693	tamoxifen
O	1693	1694	,
O	1695	1698	OFS
O	1699	1706	results
O	1707	1709	in
O	1710	1714	more
O	1715	1725	menopausal
O	1726	1734	symptoms
O	1735	1738	and
O	1739	1745	sexual
O	1746	1757	dysfunction
O	1757	1758	,
O	1759	1764	which
O	1765	1776	contributes
O	1777	1779	to
O	1780	1788	inferior
O	1789	1793	self
O	1793	1794	-
O	1794	1802	reported
O	1803	1809	health
O	1809	1810	-
O	1810	1817	related
O	1818	1825	quality
O	1826	1828	of
O	1829	1833	life
O	1833	1834	.

O	1835	1842	Because
O	1843	1845	of
O	1846	1851	early
O	1852	1859	closure
O	1859	1860	,
O	1861	1865	this
O	1866	1871	study
O	1872	1874	is
O	1875	1887	underpowered
O	1888	1891	for
O	1892	1899	drawing
O	1900	1911	conclusions
O	1912	1917	about
O	1918	1921	the
O	1922	1928	impact
O	1929	1931	on
O	1932	1940	survival
O	1941	1945	when
O	1946	1952	adding
O	1953	1956	OFS
O	1957	1959	to
O	1960	1969	tamoxifen
O	1969	1970	.
